Table 4 Unadjusted and adjusted logistic regression analysis of the associations between IL28B rs12979860-CC and rs8099917-TT and SVR12 to triple therapy according to previous HCV treatment group
All patients (105 patients) | Naïve, interruption due to SEs, viral breakthrough and relapsers (74 patients) | Partial and null reponders (31 patients) | |
|---|---|---|---|
SVR12 (95% CI) | 65.7% (56.6–74.8) | 75.7% (65.9–85.5) | 41.9% (24.5–59.3) |
IL28B rs12979860-CC | |||
Frequency (95% CI) | 21.9% (14.0–29.8) | 27% (16.9–37.1) | 9.7% (0.0–20.1) |
Unadjusted OR (95% CI) | 4.4 (1.23–16.33) | 8.7 (1.08–70.67) | 0.67 (0.05–8.24) |
Adjusted OR (95% CI) | 3.97 (1.07–14.72) | 7.3 (0.88–61.18) | 0.59 (0.47–7.43) |
Sensitivity (95% CI) | 29.0% (19.0–41.3) | 33.9% (22.2–47.9) | 7.7% (0.4–37.9) |
Specificity (95% CI) | 91.7% (76.4–97.8) | 94.4% (70.6–99.7) | 88.9% (63.9–98.1) |
PPV (95% CI) | 87.0% (65.3–96.6) | 95.0% (73.1–99.7) | 33.3% (1.8–87.5) |
NPV (95% CI) | 40.2% (29.7–51.7) | 31.5% (19.9–45.7) | 57.1% (37.4–75.0) |
IL28B rs8099917-TT | |||
Frequency (95% CI) | 42.8% (33.4–52.4) | 47.3% (35.9–58.7) | 32.3% (15.8–48.8) |
Unadjusted OR (95% CI) | 2.20 (0.94–5.17) | 4.3 (1.27–14.84) | 0.47 (0.10–2.34) |
Adjusted OR (95% CI) | 0.52 (0.17–14.72) | 0.46 (0.12–1.82) | 0.39 (0.04–4.35) |
Sensitivity (95% CI) | 49.3% (37.1–61.5) | 55.4% (41.6–68.4) | 23.1% (6.2–54.0) |
Specificity (95% CI) | 69.4% (51.7–83.1) | 77.8% (51.9–92.6) | 61.1% (36.1–81.7) |
PPV (95% CI) | 75.6% (60.1–86.6) | 88.6% (72.3–96.3) | 30.0% (8.1–64.6) |
NPV (95% CI) | 41.7% (29.3–55.1) | 35.9% (21.7–52.8) | 52.4% (30.3–73.6) |